<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602108</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000583007</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MCS314</secondary_id>
    <secondary_id>806-04</secondary_id>
    <nct_id>NCT00602108</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Women Undergoing Lumpectomy for Stage I or Stage IIA Breast Cancer</brief_title>
  <official_title>Phase II Study of Intra-operative Electron Irradiation and Hypofractionated External Beam Irradiation After Lumpectomy in Patients With Stage T1N0M0 or T2N0M0 Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving&#xD;
      intraoperative radiation therapy after lumpectomy followed by external-beam radiation therapy&#xD;
      may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well radiation therapy&#xD;
      works in treating women undergoing lumpectomy for stage I or stage IIA breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the feasibility and acute patient tolerance of intraoperative electron&#xD;
           irradiation (IOERT) and hypofractionated external-beam irradiation (HYPORT) after&#xD;
           lumpectomy for patients with stage I-IIA breast cancer treated with breast conservation&#xD;
           therapy.&#xD;
&#xD;
        -  To determine the local tumor control and distant tumor control rates for patients with&#xD;
           stage I-IIA breast cancer treated with breast conservation therapy using IOERT and&#xD;
           HYPORT after lumpectomy.&#xD;
&#xD;
        -  To determine the long-term side effects and cosmetic outcome of IOERT to tumor bed and&#xD;
           HYPORT after lumpectomy for patients with stage I-IIA breast cancer.&#xD;
&#xD;
      OUTLINE: Patients undergo lumpectomy per standard procedures. Patients undergo intraoperative&#xD;
      electron irradiation (IOERT) to the tumor bed right after completion of lumpectomy with&#xD;
      axillary lymph node dissection or sentinel lymph node biopsy.&#xD;
&#xD;
      Beginning 2-6 weeks after lumpectomy with axillary lymph node dissection/sentinel lymph node&#xD;
      sampling and IOERT, patients receive hypofractionated external-beam irradiation once daily&#xD;
      for 16 days.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 months, every 6 months for 5&#xD;
      years, and then annually thereafter for 8 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity: Up to 3 months post external beam radiation therapy</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intraoperative radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary invasive breast carcinoma&#xD;
&#xD;
               -  Stage I-IIA disease (T1, N0, M0 or T2, N0, M0)&#xD;
&#xD;
               -  Pathologically determined single, discrete, and well-defined primary tumor â‰¤ 5 cm&#xD;
                  in diameter&#xD;
&#xD;
                    -  Pathologically negative surgical margins&#xD;
&#xD;
          -  No multicentric disease and/or diffuse malignant appearing microcalcifications&#xD;
&#xD;
               -  Micro-calcifications must be focal&#xD;
&#xD;
                    -  Specimen radiograph is required after lumpectomy for tumors associated with&#xD;
                       malignant appearing calcifications to assure removal of all malignant&#xD;
                       appearing calcifications&#xD;
&#xD;
                    -  Specimen radiograph is optional if the tumor appears as a discrete mass on&#xD;
                       mammogram&#xD;
&#xD;
          -  No axillary lymph node involvement&#xD;
&#xD;
          -  No evidence of metastatic breast cancer&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  No pre-existing collagen vascular disease except rheumatoid arthritis that does not&#xD;
             require immunosuppressive therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior irradiation to the area of planned radiation field&#xD;
&#xD;
          -  No prior placement of breast prosthesis in the treated breast&#xD;
&#xD;
          -  Concurrent hormonal therapy with external-beam irradiation allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William W. Wong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>William Wailing Wong, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

